ASH Impact Series: Ruben Mesa, MD - Examining the Current Role of Ruxolitinib in Myelofibrosis

Ruben Mesa, MD, discusses ruxolitinib, the front-line therapy for patients with myelofibrosis, as well as whether combination therapy should be considered in myelofibrosis, and more. Dr. Mesa presented on the topic at the 2016 ASH Meeting on Hematologic Malignancies in a session titled "How I Treat Myelofibrosis Patients Who Have 'Failed' Ruxolitinib." Visit https://ashondemand.org/ for more on this topic and to watch other educational videos from ASH.